Welcome to our dedicated page for Kiromic Biopharma news (Ticker: KRBP), a resource for investors and traders seeking the latest updates and insights on Kiromic Biopharma stock.
Kiromic BioPharma Inc (KRBP) is a pioneering biopharmaceutical company dedicated to the development of advanced diagnostic and therapeutic solutions specifically targeting solid tumors and hematologic malignancies. Leveraging a robust portfolio of patented cancer-associated biomarkers and small molecules, Kiromic focuses on creating innovative clinical diagnostic tools and personalized immunotherapy strategies designed to improve patient outcomes, reduce suffering, and extend survival times.
Kiromic's core business revolves around its groundbreaking work in developing rapid detection mechanisms for cancer-associated antigens. This early detection capability can lead to earlier diagnoses and more accurate monitoring of patients' responses to treatments, potentially revolutionizing the field of cancer care. The company's cancer-associated biomarkers are instrumental in designing bespoke, cancer-specific targeted immunotherapies that promise higher efficacy and fewer side effects compared to traditional treatments.
Recent achievements by Kiromic BioPharma include significant advancements in their diagnostic and therapeutic programs. The company is actively engaged in several promising projects aimed at enhancing the precision and effectiveness of cancer treatments. Through strategic partnerships and collaborations, Kiromic continues to expand its research and development capabilities, constantly pushing the boundaries of cancer treatment innovation.
Financially, Kiromic BioPharma is committed to maintaining a stable and growing financial health, ensuring the sustainability of its ambitious projects and ongoing research. The company regularly updates stakeholders about its financial performance and significant milestones achieved, ensuring transparency and fostering investor confidence.
Noteworthy projects currently underway include the development of next-generation diagnostic tools that promise greater accuracy in detecting cancer-associated antigens, and the creation of more effective personalized immunotherapy treatments. By focusing on these critical areas, Kiromic aims to make substantial contributions to the field of oncology, offering hope and improved outcomes for cancer patients worldwide.
For the latest updates and relevant information about Kiromic BioPharma, including performance, events, and developments, investors and stakeholders are encouraged to follow the latest news releases.
Kiromic BioPharma (OTCQB: KRBP) has reported favorable eight-month follow-up results from the first patient in its Deltacel-01 Phase 1 clinical trial. The trial is evaluating Deltacel™ (KB-GDT-01), an allogeneic, off-the-shelf, Gamma Delta T-cell therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed standard therapies.
Key findings include:
- 20% tumor size reduction at eight months post-treatment
- No new tumor lesions detected
- Eight-month progression-free survival
- Improvement from 13% reduction at six months post-treatment
The patient is being treated at the Beverly Hills Cancer Center. Kiromic expects to report additional follow-up results from the fourth and fifth patients in August.
Kiromic BioPharma (OTCQB: KRBP) is advancing its Deltacel-01 Phase 1 clinical trial to the Expansion Phase following a positive assessment from the Safety Monitoring Committee. The trial evaluates Deltacel™, an allogeneic, off-the-shelf, Gamma Delta T-cell therapy for stage 4 metastatic non-small cell lung cancer patients who have failed standard therapies. The company plans to begin enrolling patients in the Expansion Phase in September, adding nine more patients to the trial.
The fifth patient in Deltacel-01 completed their 30-day visit with a favorable safety profile and no dose-limiting toxicities. Kiromic expects to report early efficacy data from this patient's two-month follow-up in August. The trial's progress marks a significant milestone in validating Kiromic's innovative gamma delta approach to cancer treatment.
Kiromic BioPharma (OTCQB: KRBP) has provided updates on its Deltacel-01 Phase 1 clinical trial, which focuses on advanced non-small cell lung cancer (NSCLC) patients non-responsive to standard treatments. The trial features Deltacel (KB-GDT-01), an allogeneic Gamma Delta T-cell therapy. Patients three and four showed stable disease at follow-ups with no dose-limiting toxicities. The second patient had a complete response in brain metastasis but later detected a new subcutaneous metastasis; a new treatment protocol has been approved by the FDA. Kiromic has also submitted a Fast Track designation request to the FDA, possibly accelerating Deltacel's development. Additionally, a fifth patient completed their safety visit with no toxicities, while the sixth patient is anticipated to enroll in July.
Kiromic BioPharma (OTCQB: KRBP) has released promising six-month follow-up results for the first patient in the Deltacel-01 Phase 1 clinical trial. This trial assesses Deltacel™ (KB-GDT-01), an off-the-shelf Gamma Delta T-cell therapy for stage 4 metastatic non-small cell lung cancer (NSCLC). The patient showed a 13% tumor reduction and no new lesions, resulting in six-month progression-free survival. No dose-limiting toxicities were reported, confirming Deltacel's safety. Kiromic plans to report further long-term results by the end of June and continues to enroll new patients in the trial.
Kiromic BioPharma (OTCQB: KRBP) reported favorable six-week results from the fourth patient in its Deltacel-01 Phase 1 clinical trial. This trial evaluates the allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy, Deltacel™ (KB-GDT-01), in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who didn't respond to standard treatments. Preliminary results show an 8.5% reduction in tumor size and no new metastatic disease sites, indicating promising early efficacy. The patient also experienced improved quality of life, including discontinuation of prescription pain medications. CEO Pietro Bersani expressed optimism about these initial findings and the upcoming results from the remaining patients in the second cohort, expected in June.
Kiromic BioPharma has announced that UPMC in Pittsburgh, PA, is now the fourth clinical trial site for their Deltacel-01 Phase 1 trial. This trial evaluates Deltacel™ (KB-GDT-01), an allogeneic, off-the-shelf, Gamma Delta T-cell therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC). Dr. Jason J. Luke, a leading expert in immuno-oncology, will serve as the principal investigator at UPMC. Preliminary safety and tolerability data from the fourth patient in Deltacel-01 are favorable, with early efficacy data expected by the end of May. The company plans to enroll the fifth and sixth patients in May and June, respectively, and activate one more trial site later this quarter.
FAQ
What is the current stock price of Kiromic Biopharma (KRBP)?
What is the market cap of Kiromic Biopharma (KRBP)?
What does Kiromic BioPharma Inc do?
What are Kiromic's core areas of focus?
How does Kiromic's technology improve cancer treatment?
What recent achievements has Kiromic BioPharma made?
How does Kiromic ensure financial stability?
What projects are Kiromic currently working on?
Why are Kiromic's biomarkers important?
How can I stay updated on Kiromic's latest developments?
What is Kiromic's mission?
How does Kiromic contribute to oncology?
